|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CAMK2G |
Gene summary for CAMK2G |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CAMK2G | Gene ID | 818 |
| Gene name | calcium/calmodulin dependent protein kinase II gamma | |
| Gene Alias | CAMK | |
| Cytomap | 10q22.2 | |
| Gene Type | protein-coding | GO ID | GO:0002790 | UniProtAcc | A0A0A0MS52 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 818 | CAMK2G | HTA11_347_2000001011 | Human | Colorectum | AD | 9.70e-12 | 6.09e-01 | -0.1954 |
| 818 | CAMK2G | HTA11_83_2000001011 | Human | Colorectum | SER | 6.75e-03 | 4.69e-01 | -0.1526 |
| 818 | CAMK2G | HTA11_696_2000001011 | Human | Colorectum | AD | 3.88e-02 | 4.02e-01 | -0.1464 |
| 818 | CAMK2G | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.51e-03 | 4.59e-01 | -0.059 |
| 818 | CAMK2G | F007 | Human | Colorectum | FAP | 1.41e-02 | -2.95e-01 | 0.1176 |
| 818 | CAMK2G | A002-C-010 | Human | Colorectum | FAP | 1.96e-04 | -2.04e-01 | 0.242 |
| 818 | CAMK2G | A001-C-207 | Human | Colorectum | FAP | 1.96e-05 | -3.02e-01 | 0.1278 |
| 818 | CAMK2G | A015-C-203 | Human | Colorectum | FAP | 6.27e-18 | -3.83e-01 | -0.1294 |
| 818 | CAMK2G | A015-C-204 | Human | Colorectum | FAP | 5.41e-06 | -2.89e-01 | -0.0228 |
| 818 | CAMK2G | A014-C-040 | Human | Colorectum | FAP | 3.05e-03 | -3.67e-01 | -0.1184 |
| 818 | CAMK2G | A002-C-201 | Human | Colorectum | FAP | 1.98e-10 | -2.41e-01 | 0.0324 |
| 818 | CAMK2G | A002-C-203 | Human | Colorectum | FAP | 7.02e-03 | -1.73e-01 | 0.2786 |
| 818 | CAMK2G | A001-C-119 | Human | Colorectum | FAP | 8.27e-07 | -3.60e-01 | -0.1557 |
| 818 | CAMK2G | A001-C-108 | Human | Colorectum | FAP | 1.18e-10 | -3.04e-01 | -0.0272 |
| 818 | CAMK2G | A002-C-205 | Human | Colorectum | FAP | 3.83e-17 | -3.98e-01 | -0.1236 |
| 818 | CAMK2G | A001-C-104 | Human | Colorectum | FAP | 7.04e-07 | -2.96e-01 | 0.0184 |
| 818 | CAMK2G | A015-C-005 | Human | Colorectum | FAP | 6.49e-05 | -2.86e-01 | -0.0336 |
| 818 | CAMK2G | A015-C-006 | Human | Colorectum | FAP | 2.88e-11 | -2.67e-01 | -0.0994 |
| 818 | CAMK2G | A015-C-106 | Human | Colorectum | FAP | 9.35e-11 | -2.84e-01 | -0.0511 |
| 818 | CAMK2G | A002-C-114 | Human | Colorectum | FAP | 3.70e-13 | -2.82e-01 | -0.1561 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016311 | Colorectum | AD | dephosphorylation | 123/3918 | 417/18723 | 1.84e-05 | 3.82e-04 | 123 |
| GO:0006470 | Colorectum | AD | protein dephosphorylation | 88/3918 | 281/18723 | 2.56e-05 | 4.89e-04 | 88 |
| GO:0010975 | Colorectum | AD | regulation of neuron projection development | 129/3918 | 445/18723 | 2.88e-05 | 5.37e-04 | 129 |
| GO:0009306 | Colorectum | AD | protein secretion | 105/3918 | 359/18723 | 1.05e-04 | 1.57e-03 | 105 |
| GO:0035592 | Colorectum | AD | establishment of protein localization to extracellular region | 105/3918 | 360/18723 | 1.18e-04 | 1.73e-03 | 105 |
| GO:0071692 | Colorectum | AD | protein localization to extracellular region | 106/3918 | 368/18723 | 1.86e-04 | 2.49e-03 | 106 |
| GO:0030073 | Colorectum | AD | insulin secretion | 61/3918 | 195/18723 | 4.28e-04 | 4.81e-03 | 61 |
| GO:0015833 | Colorectum | AD | peptide transport | 77/3918 | 264/18723 | 8.90e-04 | 8.60e-03 | 77 |
| GO:0090257 | Colorectum | AD | regulation of muscle system process | 73/3918 | 252/18723 | 1.46e-03 | 1.24e-02 | 73 |
| GO:0030072 | Colorectum | AD | peptide hormone secretion | 68/3918 | 236/18723 | 2.39e-03 | 1.85e-02 | 68 |
| GO:0002790 | Colorectum | AD | peptide secretion | 69/3918 | 242/18723 | 2.97e-03 | 2.22e-02 | 69 |
| GO:0042886 | Colorectum | AD | amide transport | 83/3918 | 301/18723 | 3.37e-03 | 2.46e-02 | 83 |
| GO:0043502 | Colorectum | AD | regulation of muscle adaptation | 31/3918 | 98/18723 | 8.45e-03 | 4.94e-02 | 31 |
| GO:00902571 | Colorectum | SER | regulation of muscle system process | 60/2897 | 252/18723 | 3.28e-04 | 5.22e-03 | 60 |
| GO:00064701 | Colorectum | SER | protein dephosphorylation | 65/2897 | 281/18723 | 4.44e-04 | 6.51e-03 | 65 |
| GO:00093061 | Colorectum | SER | protein secretion | 79/2897 | 359/18723 | 5.99e-04 | 8.19e-03 | 79 |
| GO:00355921 | Colorectum | SER | establishment of protein localization to extracellular region | 79/2897 | 360/18723 | 6.54e-04 | 8.77e-03 | 79 |
| GO:00716921 | Colorectum | SER | protein localization to extracellular region | 80/2897 | 368/18723 | 8.13e-04 | 1.01e-02 | 80 |
| GO:00435021 | Colorectum | SER | regulation of muscle adaptation | 27/2897 | 98/18723 | 1.54e-03 | 1.65e-02 | 27 |
| GO:00109751 | Colorectum | SER | regulation of neuron projection development | 92/2897 | 445/18723 | 1.85e-03 | 1.89e-02 | 92 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0541730 | Oral cavity | OSCC | Lipid and atherosclerosis | 131/3704 | 215/8465 | 2.20e-07 | 1.45e-06 | 7.37e-07 | 131 |
| hsa0472220 | Oral cavity | OSCC | Neurotrophin signaling pathway | 74/3704 | 119/8465 | 3.55e-05 | 1.49e-04 | 7.58e-05 | 74 |
| hsa051526 | Oral cavity | OSCC | Tuberculosis | 105/3704 | 180/8465 | 5.00e-05 | 2.04e-04 | 1.04e-04 | 105 |
| hsa0406627 | Oral cavity | OSCC | HIF-1 signaling pathway | 68/3704 | 109/8465 | 6.30e-05 | 2.48e-04 | 1.26e-04 | 68 |
| hsa0401216 | Oral cavity | OSCC | ErbB signaling pathway | 55/3704 | 85/8465 | 7.46e-05 | 2.81e-04 | 1.43e-04 | 55 |
| hsa0521410 | Oral cavity | OSCC | Glioma | 49/3704 | 75/8465 | 1.27e-04 | 4.50e-04 | 2.29e-04 | 49 |
| hsa04114 | Oral cavity | OSCC | Oocyte meiosis | 74/3704 | 131/8465 | 2.13e-03 | 5.75e-03 | 2.92e-03 | 74 |
| hsa0436014 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
| hsa05012113 | Oral cavity | OSCC | Parkinson disease | 188/3704 | 266/8465 | 1.82e-19 | 1.52e-17 | 7.75e-18 | 188 |
| hsa05022112 | Oral cavity | OSCC | Pathways of neurodegeneration - multiple diseases | 292/3704 | 476/8465 | 1.60e-15 | 4.47e-14 | 2.28e-14 | 292 |
| hsa05415113 | Oral cavity | OSCC | Diabetic cardiomyopathy | 131/3704 | 203/8465 | 1.33e-09 | 1.49e-08 | 7.57e-09 | 131 |
| hsa05205111 | Oral cavity | OSCC | Proteoglycans in cancer | 128/3704 | 205/8465 | 4.00e-08 | 3.12e-07 | 1.59e-07 | 128 |
| hsa05417113 | Oral cavity | OSCC | Lipid and atherosclerosis | 131/3704 | 215/8465 | 2.20e-07 | 1.45e-06 | 7.37e-07 | 131 |
| hsa04722110 | Oral cavity | OSCC | Neurotrophin signaling pathway | 74/3704 | 119/8465 | 3.55e-05 | 1.49e-04 | 7.58e-05 | 74 |
| hsa0515211 | Oral cavity | OSCC | Tuberculosis | 105/3704 | 180/8465 | 5.00e-05 | 2.04e-04 | 1.04e-04 | 105 |
| hsa04066112 | Oral cavity | OSCC | HIF-1 signaling pathway | 68/3704 | 109/8465 | 6.30e-05 | 2.48e-04 | 1.26e-04 | 68 |
| hsa0401217 | Oral cavity | OSCC | ErbB signaling pathway | 55/3704 | 85/8465 | 7.46e-05 | 2.81e-04 | 1.43e-04 | 55 |
| hsa0521416 | Oral cavity | OSCC | Glioma | 49/3704 | 75/8465 | 1.27e-04 | 4.50e-04 | 2.29e-04 | 49 |
| hsa041141 | Oral cavity | OSCC | Oocyte meiosis | 74/3704 | 131/8465 | 2.13e-03 | 5.75e-03 | 2.92e-03 | 74 |
| hsa0436015 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CAMK2G | SNV | Missense_Mutation | c.191T>C | p.Ile64Thr | p.I64T | Q13555 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | |
| CAMK2G | SNV | Missense_Mutation | novel | c.319N>G | p.Tyr107Asp | p.Y107D | Q13555 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.637) | TCGA-A8-A08B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| CAMK2G | SNV | Missense_Mutation | novel | c.532C>A | p.Pro178Thr | p.P178T | Q13555 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-E2-A56Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| CAMK2G | insertion | Frame_Shift_Ins | novel | c.316_317insGTGCAGAAGACATGGTTTCTGTCCTG | p.Glu106GlyfsTer41 | p.E106Gfs*41 | Q13555 | protein_coding | TCGA-A8-A08B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
| CAMK2G | insertion | Nonsense_Mutation | novel | c.520_521insGACATACAA | p.Phe174delinsTer | p.F174delins* | Q13555 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CAMK2G | SNV | Missense_Mutation | c.1033G>C | p.Glu345Gln | p.E345Q | Q13555 | protein_coding | tolerated_low_confidence(0.31) | benign(0.062) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD | |
| CAMK2G | SNV | Missense_Mutation | novel | c.709G>A | p.Glu237Lys | p.E237K | Q13555 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.986) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| CAMK2G | SNV | Missense_Mutation | novel | c.168G>T | p.Gln56His | p.Q56H | Q13555 | protein_coding | deleterious_low_confidence(0) | benign(0.182) | TCGA-VS-A9U7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CAMK2G | SNV | Missense_Mutation | c.787N>A | p.Ala263Thr | p.A263T | Q13555 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CAMK2G | SNV | Missense_Mutation | c.712N>C | p.Trp238Arg | p.W238R | Q13555 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | LINIFANIB | LINIFANIB | ||
| 818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | LITHIUM | LITHIUM | 12614997 | |
| 818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 178102336 | BOSUTINIB | |
| 818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | CYC-116 | CYC-116 | ||
| 818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | ANTIDEPRESSANTS | 12614997 | ||
| 818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | GEFITINIB | GEFITINIB | ||
| 818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | SP-600125 | SP-600125 | ||
| 818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | TAE-684 | TAE-684 | ||
| 818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | LY-2090314 | LY-2090314 | ||
| 818 | CAMK2G | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, ENZYME | DOVITINIB | DOVITINIB |
| Page: 1 2 3 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |